Abiomed (ABMD) Tops Q3 EPS by 16c; Raises Low End of FY Revenues Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. ANET
8. SPY
9. XYZ
10. CVS

Go back to Abiomed (ABMD) Tops Q3 EPS by 16c; Raises Low End of FY Revenues Guidance

Abiomed Announces Record Revenue of $261 Million, up 13% Year Over Year

February 3, 2022 7:00 AM EST

Increasing Low End of Guidance: $1,025 Million - $1,030 Million, up 21% - 22%

DANVERS, Mass.--(BUSINESS WIRE)-- ABIOMED, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced financial results for the quarter ended December 31, 2021.

Q3 financial summary and operational highlights:

Revenue for the quarter totaled $261 million, an increase of 13% compared to $232 million during the same period of the prior fiscal year. In constant currency,* revenue increased 14% compared to the same period of the prior fiscal year. Worldwide Impella®... More